About Us
Our Approach
Our Programs
Overview
Friedreich Ataxia Program
Fuchs Endothelial
Corneal Dystrophy
Huntington’s Disease
Myotonic Dystrophy Program
Research Programs
Patients
Friedreich Ataxia
Expanded Access Programs
Investors
Home
News & Events
News Releases
Events & Presentation
Stock Information
Stock Quote & Chart
Corporate Governance
Documents & Charters
Management Team
Board of Directors
Committee Composition
Financials & Filings
SEC Filings
Investor Resources
FAQs
Email Alerts
Contact IR
Careers
Design Therapeutics Launches with $45 Million to Develop a New Class of Disease-Modifying Therapies for Serious Degenerative Disorders